An extract of phase II and III trials on recent developments in managing neuropathic pain syndromes: diabetic peripheral neuropathy, trigeminal neuralgia, and postherpetic neuralgia

• Published in: Expert opinion on emerging drugs p. 1
• Main Authors: Upshaw, William C, Soileau, Lenise G, Storey, Nicholas R, Perkinson, Kassady A, Luther, Patrick M, Spillers, Noah J, Robinson, Christopher L, Miller, Benjamin C, Ahmadzadeh, Shahab, Viswanath, Omar, Shekoohi, Sahar, Kaye, Alan D
• Format: Journal Article
• Language: English
• Published: England 02.04.2024
• Subjects: diabetic peripheral neuropathy; neuralgia; chronic pain; trigeminal neuralgia; Neuropathic pain
• ISSN: 1744-7623
• DOI: 10.1080/14728214.2024.2323193

Neuropathic pain (NP) conditions involve lesions to the somatosensory nervous system leading to chronic and debilitating pain. Many patients suffering from NP utilize pharmacological treatments with various drugs that seek to reduce pathologic neuronal states. However, many of these drugs show poor efficacy as well as cause significant adverse effects. Because of this, there is a major need for the development of safer and more efficacious drugs to treat NP. In this review, we analyzed current treatments being developed for a variety of NP conditions. Specifically, we sought drugs in phase II/III clinical trials with indications for NP conditions. Various databases were searched including Google Scholar, PubMed, and clinicaltrials.gov. All the mentioned targets for treatments of NP seem to be promising alternatives for existing treatments that often possess poor side effect profiles for patients. However, gene therapy potentially offers the unique ability to inject a plasmid containing growth factors leading to nerve growth and repair. Because of this, gene therapy appears to be the most intriguing new treatment for NP.